- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:42 | Glucotrack GAAP EPS of -$0.67 | 1 | Seeking Alpha | ||
| Mi | Glucotrack, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mi | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 236 | GlobeNewswire (Europe) | On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device... ► Artikel lesen | |
| Di | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Di | Glucotrack, Inc.: Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor | 170 | GlobeNewswire (Europe) | RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization... ► Artikel lesen | |
| 16.04. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 16.04. | Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe | 1 | MassDevice | ||
| 03.04. | Glucotrack, Inc.: Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor | 1 | GlobeNewswire (USA) | ||
| 31.03. | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | GlucoTrack, Inc.: Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights | 64 | GlobeNewswire (Europe) | Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption... ► Artikel lesen | |
| 31.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | GCTK-Aktie stürzt | 4 | Investing.com Deutsch | ||
| 13.03. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.02. | Glucotrack, Inc.: Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member | 1 | GlobeNewswire (USA) | ||
| 26.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | 1 | FierceBiotech | ||
| 05.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM | - | RTTNews | ||
| 04.02. | Glucotrack announces pricing of $3M public offering | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack sets terms for $3 million public stock offering | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 63,25 | +1,28 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Quartalsergebnis
Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose
13.05.2025 / 07:45... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,129 | -5,15 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
| SYNLAB | 12,940 | +0,47 % | Synlab Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| NUGEN MEDICAL DEVICES | 0,040 | -11,01 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
| UNIDOC HEALTH | 0,185 | 0,00 % | UniDoc Health Corp.: UniDoc Provides Update on Marketing Engagement | VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,802 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 3,030 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,015 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,244 | -21,29 % | Co-Diagnostics GAAP EPS of -$0.24 beats by $0.03, revenue of $0.05M misses by $0.14M | ||
| CYTOSORBENTS | 0,697 | -6,82 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| VERU | 0,450 | -0,49 % | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| QUIDELORTHO | 29,800 | -1,32 % | SA analyst downgrades: QDEL, AMCX, PLYM, DAY |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+0,33 %) liegt der Kurs bei 0,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.